<DOC>
	<DOCNO>NCT02642432</DOCNO>
	<brief_summary>The purpose study assess safety efficacy ABT-493/ABT-530 follow 12 week treatment adult chronic Hepatitis C Virus Infection genotype 1 , 2 , 4 , 5 6 infection compensate cirrhosis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ABT-493/ABT-530 Adults With Chronic Hepatitis C Virus Genotype 1 , 2 , 4 , 5 6 Infection Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Screening laboratory result indicate hepatitis C virus ( HCV ) Genotype 1 , 2 , 4 , 5 6 infection Chronic HCV infection Subject must HCV treatmentna√Øve fail prior HCV treatment Subject must document compensated cirrhosis current past clinical evidence decompensated liver disease Positive test result screen Hepatitis B surface antigen antihuman immunodeficiency virus antibody HCV genotype perform screen indicate coinfection 1 HCV genotype Consideration investigator , reason , subject unsuitable candidate receive ABT493/ABT530</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCV Genotype 1</keyword>
	<keyword>HCV Genotype 4</keyword>
	<keyword>HCV Genotype 2</keyword>
	<keyword>Cirrhotic</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>HCV Genotype 5</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV Genotype 6</keyword>
</DOC>